Research Analysts Offer Predictions for Vir Biotechnology, Inc.’s FY2024 Earnings (NASDAQ:VIR)

Vir Biotechnology, Inc. (NASDAQ:VIR) – Research analysts at HC Wainwright increased their FY2024 earnings per share estimates for shares of Vir Biotechnology in a research report issued on Tuesday, May 7th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of ($3.13) for the year, up from their prior estimate of ($3.43). HC Wainwright has a “Buy” rating and a $110.00 price objective on the stock. The consensus estimate for Vir Biotechnology’s current full-year earnings is ($4.04) per share. HC Wainwright also issued estimates for Vir Biotechnology’s Q1 2025 earnings at ($0.80) EPS, Q2 2025 earnings at ($0.88) EPS, Q3 2025 earnings at ($0.96) EPS, Q4 2025 earnings at ($0.58) EPS, FY2025 earnings at ($3.10) EPS, FY2026 earnings at ($2.13) EPS, FY2027 earnings at ($1.68) EPS and FY2028 earnings at ($0.61) EPS.

Vir Biotechnology (NASDAQ:VIR) last posted its quarterly earnings results on Thursday, May 2nd. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.99) by $0.51. Vir Biotechnology had a negative return on equity of 32.58% and a negative net margin of 677.69%. The business had revenue of $56.38 million for the quarter, compared to analyst estimates of $11.71 million. During the same quarter in the previous year, the firm earned ($1.06) EPS. The company’s quarterly revenue was down 10.5% compared to the same quarter last year.

Several other brokerages have also issued reports on VIR. Needham & Company LLC restated a “buy” rating and issued a $15.00 price objective on shares of Vir Biotechnology in a report on Friday, May 3rd. JPMorgan Chase & Co. boosted their price objective on shares of Vir Biotechnology from $10.00 to $12.00 and gave the company a “neutral” rating in a report on Friday, May 3rd. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, Vir Biotechnology has a consensus rating of “Moderate Buy” and a consensus target price of $33.57.

Vir Biotechnology Stock Down 3.9 %

NASDAQ VIR opened at $9.54 on Thursday. Vir Biotechnology has a 52 week low of $7.61 and a 52 week high of $27.48. The business’s fifty day simple moving average is $9.73 and its 200-day simple moving average is $9.64. The firm has a market cap of $1.28 billion, a PE ratio of -2.38 and a beta of 0.47.

Insider Buying and Selling at Vir Biotechnology

In other news, Director George A. Scangos sold 17,722 shares of the business’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $11.65, for a total transaction of $206,461.30. Following the completion of the transaction, the director now directly owns 112,989 shares of the company’s stock, valued at $1,316,321.85. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other news, CEO Backer Marianne De sold 72,995 shares of the stock in a transaction dated Wednesday, April 3rd. The stock was sold at an average price of $9.46, for a total value of $690,532.70. Following the transaction, the chief executive officer now owns 678,457 shares in the company, valued at approximately $6,418,203.22. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director George A. Scangos sold 17,722 shares of the business’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $11.65, for a total value of $206,461.30. Following the sale, the director now owns 112,989 shares of the company’s stock, valued at approximately $1,316,321.85. The disclosure for this sale can be found here. Insiders sold a total of 152,831 shares of company stock valued at $1,525,844 in the last three months. 15.60% of the stock is owned by corporate insiders.

Institutional Trading of Vir Biotechnology

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Texas Permanent School Fund Corp grew its stake in Vir Biotechnology by 1.4% during the 1st quarter. Texas Permanent School Fund Corp now owns 74,977 shares of the company’s stock worth $760,000 after buying an additional 1,012 shares during the last quarter. Ballentine Partners LLC grew its position in shares of Vir Biotechnology by 9.2% during the first quarter. Ballentine Partners LLC now owns 13,704 shares of the company’s stock worth $139,000 after acquiring an additional 1,160 shares during the last quarter. Arizona State Retirement System increased its holdings in shares of Vir Biotechnology by 6.0% in the 4th quarter. Arizona State Retirement System now owns 26,271 shares of the company’s stock valued at $264,000 after acquiring an additional 1,476 shares during the period. Fifth Third Bancorp boosted its stake in Vir Biotechnology by 69.3% during the 3rd quarter. Fifth Third Bancorp now owns 3,941 shares of the company’s stock worth $37,000 after purchasing an additional 1,613 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its position in Vir Biotechnology by 96.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,448 shares of the company’s stock worth $32,000 after purchasing an additional 1,692 shares during the last quarter. Institutional investors and hedge funds own 65.32% of the company’s stock.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand.